Kymera to Present at J.P. Morgan Healthcare Conference Jan 9

TL;DR

**Kymera's presenting at J.P. Morgan on Jan 9, watch for potential news.**

AI Summary

Kymera Therapeutics, Inc. filed an 8-K on January 4, 2024, to announce that they will be participating in the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. This matters to investors because such conferences are often used by companies to provide updates on their pipeline, clinical trials, or financial outlook, which can significantly impact stock performance. Any new information shared at this event could influence Kymera's stock price (KYMR).

Why It Matters

This filing signals an upcoming event where Kymera Therapeutics (KYMR) may share important updates, potentially affecting investor sentiment and stock valuation. Investors should monitor for news from the conference.

Risk Assessment

Risk Level: low — This filing is purely informational about an upcoming event and does not disclose any immediate negative or positive financial impacts.

Analyst Insight

A smart investor would add January 9, 2024, to their calendar and monitor news releases or webcasts from Kymera Therapeutics (KYMR) for any significant announcements made during the J.P. Morgan Healthcare Conference.

Key Players & Entities

• Kymera Therapeutics, Inc. (company) — the registrant filing the 8-K
• January 4, 2024 (date) — date of earliest event reported and filing date
• January 9, 2024 (date) — date of the 42nd Annual J.P. Morgan Healthcare Conference
• J.P. Morgan Healthcare Conference (company) — the event where Kymera will present

Forward-Looking Statements

• Kymera Therapeutics will provide an update on its clinical pipeline or financial outlook at the J.P. Morgan Healthcare Conference. (Kymera Therapeutics, Inc.) — medium confidence, target: 2024-01-09

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share KYMR The Nasdaq

Filing Documents

• d378650d8k.htm (8-K) — 36KB
• d378650dex991.htm (EX-99.1) — 20KB
• g378650gdsp1.jpg (GRAPHIC) — 5KB
• 0001193125-24-001884.txt ( ) — 193KB
• kymr-20240104.xsd (EX-101.SCH) — 3KB
• kymr-20240104_lab.xml (EX-101.LAB) — 18KB
• kymr-20240104_pre.xml (EX-101.PRE) — 11KB
• d378650d8k_htm.xml (XML) — 3KB

01

Item 7.01 Regulation FD Disclosure. On January 4 2024, Kymera Therapeutics, Inc. (the "Company") issued a press release, a copy of which is furnished herewith as Exhibit 99.1. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

01

Item 8.01 Other Events On January 4, 2024, the Company announced two preclinical programs that each have the potential to address multiple immune-mediated diseases, each with considerable market potential. The new programs target STAT6, the obligate and specific transcription factor of the interleukin-4/interleukin-13 receptor ("IL-4/IL-13") pathway, and TYK2, the key scaffolding kinase of the interleukin-21/interferon ("IL-23/IFN") pathways. These represent two essential signaling nodes in genetically and clinically validated pathways driving inflammation in autoimmune diseases that are undrugged or inadequately drugged with other technologies. The Company's immunology pipeline now includes the Company's wholly-owned STAT6 (KT-621) and TYK2 (KT-294) degraders and its IRAK4 degrader (KT-474): STAT6 degrader program (KT-621) STAT6 is an essential transcription factor specific to the IL-4/IL-13 signaling pathway and the central driver of Type 2 inflammation in allergic diseases. STAT6 is a genetically validated target and the pathway has been clinically validated by approved IL-4/IL-13-targeting biologics, including dupilumab. In preclinical studies, KT-621, the Company's first-in-class oral STAT6 degrader, demonstrated full inhibition of IL-4/IL-13 pathway in all relevant human cell contexts with picomolar potency that was superior to dupilumab, and equivalent or superior efficacy to dupilumab in multiple preclinical efficacy studies. In addition, at low oral doses, KT-621 demonstrated near full in vivo STAT6 degradation and was well-tolerated in multiple preclinical toxicity studies. KT-621, a once daily oral small molecule degrader with a preclinical biologics-like efficacy profile, has the potential to have broad activity across multiple diseases, including atopic dermatitis, asthma, chronic obstructive pulmonary disorder, eosinophilic esophagitis and chronic rhinosinusitis with nasal polyps, among others. The Company expects to initiate a Phase 1 clinical

01

Item 9.01. Exhibits (d) Exhibits Exhibit No. Description 99.1 Press release issued by Kymera Therapeutics, Inc. on January 4, 2024. 104 Cover Page Interactive Data SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Kymera Therapeutics, Inc. Date: January 4, 2024 By: /s/ Nello Mainolfi Nello Mainolfi, Ph.D. Founder, President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR